A

    Arcus Biosciences Inc (RCUS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $29.25
    +0.05 (+0.15%)

    Market Cap: $3.67B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    65%(22/34)
    Avg Surprise
    +26.95%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.88
    Range$-1.04 - $-0.69
    7 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.83+5.6%
    60d ago$-0.83+6.3%
    30d ago$-0.83+6.3%
    7d ago$-0.91-3.6%
    Current$-0.88
    Revenue Consensus
    $13M
    Range$6M - $25M
    9 analysts
    Dec 31, 2026
    EPS Consensus$-1.00
    Range$-1.83 - $-0.27
    7 analysts
    Revenue Consensus
    $14M
    Range$-6284900 - $44M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.00---
    Sep 26EST
    		-$-0.88---
    Jun 26
    		$-0.72$-0.98+26.53%Beat-
    Mar 26
    		$-1.02$-0.83-22.89%Miss+10.5%
    Dec 25
    		$-0.89$-1.10+19.09%Beat+13.6%
    Sep 25
    		$-1.27$-1.29+1.55%Beat-27.0%
    Jun 25
    		$0.00N/A+100.00%Beat+100.0%
    Mar 25
    		$-1.14$-1.01-12.87%Miss-700.0%
    Dec 24
    		$-1.03$-1.20+14.39%Beat+4.6%
    Sep 24
    		$-1.00$-1.07+6.54%Beat-6.4%
    Jun 24
    		$-1.02$-1.39+26.62%Beat+1.9%
    Mar 24
    		$0.19N/A+118.45%Beat+117.4%
    Dec 23
    		$-1.08$-1.00-8.00%Miss-16.1%
    Sep 23
    		$-0.94$-1.10+14.55%Beat-4.4%
    Jun 23
    		$-1.04$-1.08+3.70%Beat-11.8%
    Mar 23
    		$-1.09$-1.17+6.84%Beat-13.5%
    Dec 22
    		$-0.93$-1.07+13.08%Beat-125.1%
    Sep 22
    		$-0.90$-1.01+10.89%Beat+18.9%
    Jun 22
    		$-0.93$-0.95+2.11%Beat+14.7%
    Mar 22
    		$-0.96$-0.84-14.29%Miss+11.1%
    Dec 21
    		$3.71$-0.74+601.35%Beat+552.4%
    Sep 21
    		$-1.11$-1.03-7.77%Miss-3800.0%
    Jun 21
    		$-1.09$-0.84-29.76%Miss-17.2%
    Mar 21
    		$-1.08$-0.83-30.12%Miss-71.4%
    Dec 20
    		$-0.82$-0.75-9.33%Miss-115.8%
    Sep 20
    		$0.03N/A+103.95%Beat+105.9%
    Jun 20
    		$-0.93$-0.58-60.34%Miss-45.3%
    Mar 20
    		$-0.63$-0.56-12.50%Miss-53.7%
    Dec 19
    		$-0.38$-0.51+25.49%Beat-35.7%
    Sep 19
    		$-0.51$-0.52+1.92%Beat-104.0%
    Jun 19
    		$-0.64$-0.41-56.10%Miss-100.0%
    Mar 19
    		$-0.41$-0.35-17.14%Miss-10.8%
    Dec 18
    		$-0.28$-0.45+37.78%Beat+26.3%
    Sep 18
    		$-0.25$-0.35+28.57%Beat-47.1%
    Jun 18
    		$-0.32$-0.40+20.00%Beat-
    Mar 18
    		$-0.37$-0.43+13.95%Beat-
    Dec 17
    		$-0.38$0.00N/AMiss-
    Mar 17
    		$-0.17$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.50EV/EBITDA3.96x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-234.10%
    ROE-90.80%ROIC-62.78%
    Financial Health
    Debt/Equity0.22xInterest Coverage-40.82x
    Current Ratio3.82xQuick Ratio3.82x
    Trading Statistics
    Beta0.81Avg Volume1.16M
    52-Week High$31.7352-Week Low$10.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$30.12
    SMA 20$29.45
    SMA 50$29.09
    SMA 200$24.42
    EMA 10$29.87
    EMA 20$29.54
    EMA 50$28.51
    EMA 200$23.97

    MACD

    Line: 0.48Signal: 0.53Hist: -0.06

    ADX

    ADX: 10.1+DI: 15.2-DI: 25.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down8.0
    PSAR$28.07

    Bollinger Bands

    Upper Band$31.33
    Lower Band$27.57
    %B Position1275%(Upper)
    Band Width0.45

    RSI (14-Day)

    Neutral
    49.7

    Momentum Oscillators

    Stoch %K47.7
    Stoch %D64.2
    Williams %R-64.4
    ROC (10d)-1.0%
    Momentum-0.30
    CCI (20d)-44.7
    MFI (14d)48.2

    Volatility Measures

    ATR (14d)$1.31(4.5%)
    StdDev (20d)0.94
    Hist Vol39.4%(Moderate)

    Volume Flow

    VWAP$28.94
    OBV45.0M
    AD Line28.7M
    CMF (20d)0.023

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.9x
    VWMA (20d)$29.37

    Pivot Points

    R3$31.45
    R2$30.94
    R1$30.08
    Pivot Point$29.57
    S1$28.70
    S2$28.19
    S3$27.33

    Advanced Oscillators

    TSI11.20
    Ultimate Osc55.5
    KST50.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$41.00M$17.00M$33.00M$26.00M$160.00M$28.00M$26.00M$48.00M$39.00M$145.00M$31.00M$32.00M
    Cost of Revenue$0$0$3.00M$0$0$0$3.00M$0$0$0$5.00M$0
    Gross Profit$41.00M$17.00M$33.00M$26.00M$160.00M$28.00M$26.00M$48.00M$39.00M$145.00M$31.00M$32.00M
    Operating Expenses$137.00M$151.00M$147.00M$168.00M$168.00M$150.00M$129.00M$153.00M$145.00M$161.00M$122.00M$112.00M
    R&D$113.00M$122.00M$121.00M$141.00M$139.00M$122.00M$101.00M$123.00M$115.00M$109.00M$93.00M$82.00M
    SG&A$24.00M$29.00M$26.00M$27.00M$29.00M$28.00M$28.00M$30.00M$30.00M$32.00M$29.00M$30.00M
    Operating Income$-96,000,000$-134,000,000$-114,000,000$-142,000,000$-8,000,000$-122,000,000$-103,000,000$-105,000,000$-106,000,000$-16,000,000$-91,000,000$-80,000,000
    Interest Income$0$0$0$0$0$0$0$0$0$13.00M$0$0
    Interest Expense$3.00M$3.00M$2.00M$3.00M$2.00M$1.00M$2.00M$1.00M$0$1.00M$0$1.00M
    Income Before Tax$-91,000,000$-128,000,000$-106,000,000$-135,000,000$0$-112,000,000$-93,000,000$-92,000,000$-93,000,000$-4,000,000$-80,000,000$-69,000,000
    Income Tax Expense$0$0$0$0$0$0$1.00M$0$0$0$1.00M$2.00M
    Net Income$-91,000,000$-128,000,000$-106,000,000$-135,000,000$0$-112,000,000$-94,000,000$-92,000,000$-93,000,000$-4,000,000$-81,000,000$-71,000,000
    EBITDA$-87,000,000$-126,000,000$-104,000,000$-133,000,000$1.00M$-112,000,000$-106,000,000$-95,000,000$-98,000,000$-19,000,000$-89,000,000$-66,000,000
    EBIT$-88,000,000$-125,000,000$-104,000,000$-132,000,000$2.00M$-111,000,000$-103,000,000$-91,000,000$-93,000,000$-16,000,000$-80,000,000$-68,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RCUS

    News

    Why Arcus Biosciences (RCUS) Is Getting Attention Today

    Arcus Biosciences (RCUS) stock is gaining attention after recent share price movements, closing at US$30.12. Investors are focused on its clinical-stage cancer pipeline, particularly the HIF-2 alpha inhibitor casdatifan, which analysts believe could significantly undervalue the stock at $38. However, despite a positive long-term outlook, its high Price-to-Sales ratio of 32.8x compared to industry averages and potential regulatory risks for its drug pipeline warrant caution.

    Simply Wall Street•8/25/26•
    Somewhat-Bullish

    Arcus Biosciences CAO Azoy sells $84,810 in stock

    Alexander Azoy, Chief Accounting Officer at Arcus Biosciences (NASDAQ:RCUS), sold 2,827 shares of common stock for $84,810 on August 21, 2026, under a Rule 10b5-1 trading plan. This sale followed the exercise of options for an equal number of shares at a lower price. The company's stock is trading near its 52-week high, with recent positive financial results for Q2 2026 surpassing analysts' expectations for both earnings and revenue.

    Investing.com•8/24/26•
    Neutral

    Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan

    Arcus Biosciences Chief Accounting Officer, Alexander Azoy, exercised stock options for 2,827 shares at $15.44 per share and simultaneously sold these shares at $30.00 per share. This transaction, executed under a Rule 10b5-1 trading plan on August 21, 2026, resulted in approximately $41,000 in pre-tax spread. Following the sale, Azoy retains 3,073 stock options expiring in 2034.

    Stock Titan•8/24/26•
    Neutral

    Arcus Biosciences (RCUS) officer eyes sale after June plan trades

    Arcus Biosciences officer Alexander Azoy has filed a Rule 144 notice for a planned sale of 2,827 shares of common stock, valued at $83,453.04, following the exercise of stock options. This follows previous 10b5-1 plan sales of 2,562 shares for $66,023.76 on June 1, 2026. The sale is scheduled for August 21, 2026, through Morgan Stanley Smith Barney LLC.

    Stock Titan•8/21/26•
    Neutral

    Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales

    Arcus Biosciences (RCUS) has seen a strong 200.8% return over the past year, driven by a partnership with Summit Therapeutics, but its valuation appears stretched with a P/S ratio of 33.0x against an industry average of 11.6x. The company's current valuation implies high investor optimism, which needs to be supported by significant progress in its pipeline, particularly the kidney cancer program, to justify its rich pricing.

    Sahm•8/21/26•
    Bearish

    Frequently Asked Questions About RCUS

    Does RCUS pay dividends?
    Arcus Biosciences Inc (RCUS) does not currently pay a regular dividend.
    What is RCUS's market cap?
    Arcus Biosciences Inc (RCUS) has a market capitalization of $3.67B with a current stock price of $29.25.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In